Cargando…

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

BACKGROUND: Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emson, Claire, Diver, Sarah, Chachi, Latifa, Megally, Ayman, Small, Cherrie, Downie, John, Parnes, Jane R., Bowen, Karin, Colice, Gene, Brightling, Chris E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550845/ https://www.ncbi.nlm.nih.gov/pubmed/33050900 http://dx.doi.org/10.1186/s12931-020-01513-x

Ejemplares similares

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
por: Emson, Claire, et al.
Publicado: (2021)

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
por: Corren, Jonathan, et al.
Publicado: (2022)

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma
por: Wechsler, Michael E., et al.
Publicado: (2020)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma
por: Carlsson, Mats, et al.
Publicado: (2019)

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis
por: Shaban Abdelgalil, Mahmoud, et al.
Publicado: (2022)

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
por: Zoumot, Zaid, et al.
Publicado: (2022)

The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Fei, et al.
Publicado: (2023)

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
por: Roy, Pooja, et al.
Publicado: (2022)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects
por: Parnes, Jane R., et al.
Publicado: (2019)

Tezepelumab treatment for allergic bronchopulmonary aspergillosis
por: Ogata, Hiroaki, et al.
Publicado: (2023)

Interleukin‐18, IL‐18 binding protein and IL‐18 receptor expression in asthma: a hypothesis showing IL‐18 promotes epithelial cell differentiation
por: Kaur, Davinder, et al.
Publicado: (2021)

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
por: Gottlow, Mattis, et al.
Publicado: (2019)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
por: Plaza, Vicente, et al.
Publicado: (2023)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4
por: Di Candia, Leonarda, et al.
Publicado: (2017)

A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men
por: Sakamoto, Kei, et al.
Publicado: (2020)

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)

Targeting TSLP in Asthma
por: Parnes, Jane R, et al.
Publicado: (2022)

Fibrocyte localisation to the ASM bundle in asthma: bidirectional effects on cell phenotype and behaviour
por: Saunders, Ruth, et al.
Publicado: (2020)

Pragmatic research and outcomes in asthma and COPD
por: Colice, Gene L
Publicado: (2012)

Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast: Highlights of the Asthma Summit 2009: Beyond the Guidelines
por: Colice, Gene, et al.
Publicado: (2010)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
por: George, Leena, et al.
Publicado: (2019)

Tiotropium in asthma: a systematic review
por: Befekadu, Elizabeth, et al.
Publicado: (2014)

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
por: Austin, Cary D., et al.
Publicado: (2020)

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
por: Busse, William W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0jeo1g5cbabjht26m0d2d82vcj